Related Experiment Video
Updated: Jul 8, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
Cardiac contractility modulation with the impulse dynamics signal: studies in dogs with chronic heart failure
1Department of Medicine & Division of Cardiovascular Medicine, Henry Ford Heart & Vascular Institute, Detroit, Michigan USA. hsabbahl@hfhs.org
Insights
Cardiac contractility modulation (CCM) offers a novel, non-pharmacologic approach to support failing hearts. This electrical signal therapy shows promise for improving heart function without the risks of traditional inotropic agents.
Area of Science:
- Cardiology
- Biomedical Engineering
- Heart Failure Research
Background:
- Positive inotropic agents for heart failure (HF) have limitations including pro-arrhythmic and positive chronotropic effects.
- Chronic use of existing inotropic agents increases mortality in advanced HF patients.
- Need for safe and effective on-demand positive inotropic support for advanced HF.
Purpose of the Study:
- To examine a novel, non-stimulatory electrical signal for modulating left ventricular (LV) contractility.
- To assess the efficacy of Cardiac Contractility Modulation (CCM) for acute positive inotropic support in a canine HF model.
Main Methods:
- Chronic heart failure induced in dogs via intracoronary microembolizations.
- Delivery of the CCM signal (Impulse Dynamics) via a lead in the great coronary vein.
- Assessment of hemodynamic parameters (cardiac output, LV peak+dP/dt, LV fractional shortening, LV ejection fraction) and cardiomyocyte function.
Main Results:
- Acute CCM signal delivery significantly improved cardiac output and LV contractility parameters.
- Functional improvements returned to baseline upon signal discontinuation.
- CCM application improved isolated cardiomyocyte shortening and calcium transient dynamics.
Conclusions:
- Pre-clinical results suggest CCM is a non-pharmacologic modality for short-term positive inotropic support in heart failure.
- CCM may serve as a useful adjunct therapy for advanced heart failure.
- Further long-term studies are required to establish chronic safety and efficacy.
Abstract:
The intravenous use of positive inotropic agents, such as sympathomimetics and phosphodiesterase inhibitors, in heart failure is limited by pro-arrhythmic and positive chronotropic effects. Chronic use of these agents, while eliciting an improvement in the quality of life of patients with advanced heart failure, has been abandoned because of marked increase in mortality when compared to placebo. Nevertheless, patients with advanced heart failure can benefit from long-term positive inotropic support if the therapy can be delivered 'on demand' and in a manner that is both safe and effective. In this review, we will examine the use of a novel, non-stimulatory electrical signal that can acutely modulate left ventricular (LV) contractility in dogs with chronic heart failure in such a way as to elicit a positive inotropic support. Cardiac contractility modulation (CCM) with the Impulse Dynamic(trade mark) signal was examined in dogs with chronic heart failure produced by intracoronary microembolizations. Delivery of the CCM signal from a lead placed in the great coronary vein for periods up to 10 minutes resulted in significant improvements in cardiac output, LV peak+dP/dt, LV fractional area of shortening and LV ejection fraction measured angiographically. Discontinuation of the signal resulted in a return of all functional parameters to baseline values. In cardiomyocytes isolated from dogs with chronic heart failure, application of the CCM signal resulted in improved shortening, rate of change of shortening and rate of change of relengthening suggesting that CCM application is associated with intrinsic improvement of cardiomyocyte function. The improvement in isolated cardiomyocyte function after application of the CCM signal was accompanied by an increase in the peak and integral of the Ca(2+) transient suggesting modulation of calcium cycling by CCM application. In a limited number of normal dogs, intermittent chronic delivery of the CCM signal for up to 7 days showed chronic maintenance of LV functional improvement. In conclusion, pre-clinical results to date with the Impulse Dynamics CCM signal indicate that this non-pharmacologic therapeutic modality can provide short-term positive inotropic support to the failing heart and as such, may be a useful adjunct in the treatment of advanced heart failure. Additional, long-term studies in dogs with heart failure are needed to establish the safety and efficacy of this therapeutic modality for the chronic treatment of this disease syndrome.
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Heart Failure II: Pathophysiology
Cardiomyopathy II: Dilated Cardiomyopathy

